TOKYO, Feb 2, 2023 – (JCN Newswire via SEAPRWire.com) – Mitsubishi Shipbuilding Co., Ltd., a Mitsubishi Heavy Industries (MHI) Group company based in Yokohama, has recently completed a conceptual study […]
TOKYO and CAMBRIDGE, Mass., Jan 30, 2023 – (JCN Newswire via SEAPRWire.com) – Eisai Co., Ltd. and Biogen Inc. announced today that an application for manufacturing and marketing approval for […]
TOKYO and CAMBRIDGE, Mass., Jan 16, 2023 – (JCN Newswire via SEAPRWire.com) – Eisai Co., Ltd. and Biogen Inc. announced today that Eisai has submitted a marketing authorization application for […]
TOKYO, Jan 11, 2023 – (JCN Newswire via SEAPRWire.com) – Eisai Co., Ltd. and Biogen Inc. (Nasdaq: BIIB) announced today that Eisai has submitted a marketing authorization application (MAA) for […]
ROCKVILLE, MD and SHENZHEN, CHINA, Jan 5, 2023 – (ACN Newswire via SEAPRWire.com) – HighTide Therapeutics Inc. (“HighTide”), a globally integrated clinical-stage biopharmaceutical company developing novel multifunctional therapies for metabolic […]
TOKYO, Dec 7, 2022 – (JCN Newswire via SEAPRWire.com) – Mitsubishi Heavy Industries, Ltd. (MHI), on December 6, signed a Memorandum of Understanding (MoU) with Guacolda Energia SpA, an independent […]
TOKYO, Nov 30, 2022 – (JCN Newswire via SEAPRWire.com) – Eisai Co., Ltd. and Biogen Inc. announced today that the results from Eisai’s large global Phase 3 confirmatory Clarity AD […]
TOKYO, Nov 30, 2022 – (JCN Newswire via SEAPRWire.com) – Eisai Co., Ltd. and Biogen Inc. announced today that the results from Eisai’s large global Phase 3 confirmatory Clarity AD […]
ROCKVILLE, MD and SHENZHEN, CHINA, Nov 17, 2022 – (ACN Newswire via SEAPRWire.com) – HighTide Therapeutics, Inc. (“HighTide”), a globally integrated clinical-stage biopharmaceutical company developing novel multifunctional therapies for metabolic […]
ROCKVILLE, MD and SHENZHEN, CHINA, Nov 16, 2022 – (ACN Newswire via SEAPRWire.com) – HighTide Therapeutics, Inc. (“HighTide”), a globally integrated clinical-stage biopharmaceutical company developing novel multifunctional therapies for metabolic […]
TOKYO, Nov 2, 2022 – (JCN Newswire via SEAPRWire.com) – Eisai Co., Ltd. announced today that it has received notification from Japan’s Ministry of Health, Labour, and Welfare (MHLW) that […]
TOKYO, Nov 2, 2022 – (JCN Newswire via SEAPRWire.com) – Eisai Co., Ltd. announced today that it has received notification that Aricept (donepezil hydrochloride), a treatment for Alzheimer’s disease and […]
HONG KONG, Aug 24, 2022 – (ACN Newswire via SEAPRWire.com) – SinoMab BioScience Limited (“SinoMab” or the “Company”, together with its subsidiaries, the “Group”, stock code: 3681.HK), a Hong Kong-based […]
TOKYO, Jul 26, 2022 – (JCN Newswire via SEAPRWire.com) – Eisai Co. Ltd announced today that the company will present research from its Alzheimer’s disease (AD) pipeline, including new data […]
ADELAIDE, AUS, Jul 20, 2022 – (ACN Newswire via SEAPRWire.com) – TrialWire(TM) Technology Platform, the most secure and rapid digital patient recruitment Platform for trial rescue, today announced the rollout […]
SHANGHAI, CHINA, May 13, 2022 – (ACN Newswire via SEAPRWire.com) – Hua Medicine (the “Company”, stock code on the main board of the Hong Kong Stock Exchange: 2552.HK) today announces […]
TOKYO and CAMBRIDGE, Mass., May 10, 2022 – (JCN Newswire via SEAPRWire.com) – Eisai Co., Ltd. and Biogen Inc. announced today that Eisai has completed the rolling submission to the […]
TOKYO, Apr 19, 2022 – (JCN Newswire via SEAPRWire.com) – ENEOS Corporation and Mitsubishi Corporation have agreed to undertake a joint feasibility study aimed at commercializing Sustainable Aviation Fuel (SAF) […]
CAMBRIDGE, Mass., and TOKYO, Mar 22, 2022 – (JCN Newswire via SEAPRWire.com) – Eisai Co., Ltd. and Biogen Inc. announced today that the latest findings on lecanemab, an investigational anti-amyloid-beta […]
